[인포스탁데일리=김현욱AI 앵커] Samsung Biologics is expected to follow the procedure for the IPO of its subsidiary, Samsung Bioepis.
If you look at the direct financing results of companies announced by the Financial Supervisory Service yesterday, the total issuance of stocks by domestic companies in April totaled 3.49 trillion won.
In particular, Samsung Biologics’ capital increase of 3.2 trillion won to acquire the stake in Samsung Bioepis had a major impact.
It is known that Samsung Biologics will be used as a fund to recover all 49% of Samsung Bioepis’ stake held by US Biogen.
In the market, attention is focused on the timing of the IPO of Samsung Bioepis.
Previously, between 2014 and 2015, Samsung Bioepis pushed for a listing on the US NASDAQ, but withdrew.
Some observers say that Samsung Biologics is following the same path as LG Chem’s LG Energy Solution physical split.
LG Chem was listed as a spin-off of LG Energy Solutions during the IPO of the electric vehicle battery business, which is a core business division.
When the kernel fell out, the share price of LG Chem plummeted in half.
Samsung Biologics is mainly engaged in consignment development and production, and Samsung Bioepis is engaged in the biosimilar business.
Experts estimate that the business areas of the two companies are different this month.
It is said that Samsung Biologics and Samsung Bioepis started as different companies from birth.
It’s different from split-listing business divisions like LG Chem.
General investors are paying close attention to the situation, weighing the gains and losses on the impact on the share price of Samsung Bioepis, a subsidiary of Samsung Biologics, when it goes public.
Kim Hyun-wook AI anchor [email protected]
© Infostock Daily Unauthorized reproduction and redistribution prohibited